health_text_en

PFIZER RANKED LEADING COMPANY IN ASIA FOR COVID-19 RESPONSE AND PATIENT-CENTRIC APPROACH BY ASIAN PATIENT GROUPS

Pfizer is ranked 1st in Australia/New Zealand region and overall 2nd in Asia in its corporate reputation from a patient perspective Asian patient groups have placed the pharma industry 1st for corporate reputation in Asia amongst other healthcare sectors Pfizer has been ranked first in its Covid-19 response, patient centricity, patient safety and bringing innovative, high-quality products amongst pharma companies […]

thaipr.net

26 ส.ค. 65

First US Patient Enrolled in SELUTION SLR IDE Peripheral Study

The first US patient has been enrolled in the FDA SELUTION4BTK (Below-the-Knee) clinical trial evaluating SELUTION SLR™, MedAlliance’s novel sirolimus-eluting balloon. This milestone follows Investigational Device Exemption (IDE) approval in the US in May 2022, with enrollment of the first patient occurring in Germany one week after approval.   “We are very excited to finally […]

thaipr.net

24 ส.ค. 65

Prominent ophthalmologist will guide Turn Bio’s search for therapies to cure eye diseases

Albert Wu, MD, PhD, a recognized advocate of using stem cell therapy to treat eye conditions, will advise company’s development of ocular tissue rejuvenation therapeutics Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today announced that Albert Wu, MD, PhD, will oversee its development of ophthalmic therapeutic products as […]

thaipr.net

23 ส.ค. 65

Menarini Group’s Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA) for the Treatment of ER+/HER2- Advanced or Metastatic Breast Cancer

Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced or metastatic breast cancer in the European Union Submission supported by results from the pivotal Phase 3 EMERALD study showing a statistically significant difference in the efficacy in favor […]

thaipr.net

22 ส.ค. 65

AMETEK Thailand Opens New Office and Centre of Excellence to Provide Customers in Southeast Asia with AMETEK’s latest Technology Solutions

AMETEK Thailand is pleased to announce that it has opened a new, state-of-the-art facility in a convenient location in Bangkok that will provide enhanced support for customers throughout the Southeast Asia region. AMETEK Thailand began operations in 2017 and continues to play an important role within AMETEK’s Southeast Asia’s ecosystem. The move to a new […]

thaipr.net

17 ส.ค. 65

Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio’s Investigational Compound Being Developed for Patients with AML

Companion diagnostic would be used following potential regulatory approval of entospletinib to screen for NPM1 mutation present in approximately one-third of all patients with AML Entospletinib is currently being studied in the Phase 3 AGILITY registrational study, with data anticipated in second half of 2023 Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming […]

thaipr.net

17 ส.ค. 65

Menarini Group’s Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer

Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from 2L and 3L ER+/HER2- advanced or metastatic breast cancer Submission supported by results from the pivotal Phase 3 EMERALD study of elacestrant showing statistically significant efficacy over current standard-of-care (SOC) medications for both the overall […]

thaipr.net

15 ส.ค. 65

MedAlliance SELUTION SLR Receives Second FDA IDE Approval

SELUTION SLR™, MedAlliance’s novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption (IDE) approval to initiate its pivotal clinical trial for the treatment of occlusive disease of the superficial femoral artery (SFA). This comes only a few months after the company received IDE approval for SELUTION SLR in the treatment of below-the-knee (BTK) indications […]

thaipr.net

10 ส.ค. 65
1 … 27 28 29 30 31 … 73

Copyright © 2026 Dataxet Limited (บริษัท ดาต้าเซ็ต จำกัด). All Rights Reserved.